|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 自体CIK细胞联合XELOX化疗治疗晚期结直肠癌的随机对照研究(英文)显示文摘Objective: To evaluate the efficacy of autologous cytokine-induced killer(CIK) cells transfusion combined with chemotherapy in patients suffered from advanced colorectal cancer. Methods: Sixty untreated patients with advanced colorectal cancer were randomly divided into two groups. The 30 patients in the control group received chemotherapy with the regimen of xeloda plus oxiplatin(XELOX). The 30 patients in the trial group were treated with chemotherapy(XELOX) in combination with autologous CIK cell transfusion. T-lymphocyte subgroups were separated and measured by flow cytometry quality of life(QOL) was determined by EORTC QLQ-C30. The short-term curative effect was evaluated via imaging examinations. The patients' median progression free survival time was estimated by Kaplan-Meier. Results: The T-lymphocyte immune activity was improved in patients received autologous CIK cell transfusion than those treated with chemotherapy alone.The subgroup of CD3+CD56+T lymphocyte was significantly increased(4.28 ± 0.45 vs 10.14 ± 1.02, P = 0.01). Short-term efficacy evaluation revealed that there was no significant difference in terms of objective response rate(ORR) between the two groups, but the disease control rate(DCR) was markedly increased(86.7% vs 56.7%, P = 0.020) in the group treated by chemotherapy plus CIK cells compared to the group treated with chemotherapy alone. The progression free survival time was 8.64 months( 95% CI 6.25-9.75 months) in control group and 10.15 months( 95% CI 7.48-12.52 months) in trial group.Compared to patients in control group, the patients in trial group had significantly longer progression-free survival(P = 0.046).The QOL assessment suggested the QOL in trial group was obviously improved than that in the control group. Compared with the control group, patients treated with autologous CIK cell transfusion scored more in the area of physical function and general health status, while the symptomatic scores in terms of pain, fatigue, nausea and vomiting and diarrhea were significantly reduced. Conclusion: Autologous CIK cell transfusion combined with chemotherapy can effectively enhance the immune activity of T-lymphocytes, prevent disease progression and improve the progression-free survival and QOL in patients with advanced colorectal cancer. | Cheng Du Zhaozhe Liu Zhenyu Ding Fang Guo Dongchu Ma Xiaodong Xie | 2013 | The Chinese-German Journal of Clinical Oncology2013，12，10： | 1 |
| 2 | Thrombopoietin induced proliferation and differentiation of fetal liver CD34^+ cells with phenotype change from hemopoiesis to neurogenesis显示文摘BACKGROUND: Previous studies have reported a neurotrophin-like motif in the N-terminal receptor binding region of the thrombopoietin (TPO) molecule, and have described localization of TPO and TPO receptor in the brain. Therefore, it is believed that TPO may be involved in regulation of neurogenesis. OBJECTIVE: To validate the effect of TPO on trans-differentiation, or differentiation from hematopoietic stem cells (HSCs) to neural stem cells (NSCs). DESIGN, TIME AND SETTING: Comparative studies were performed from March 2004 to April 2007 at the Department of Experimental Medicine, Northern Hospital, and the Department of Immunology, Fourth Military Medical University of Chinese PLA. MATERIALS: Human fetal liver (FL) was obtained from fetuses after water-balloon abortion. Gestational age ranged from 16 to 20 weeks. The study was approved by the Institutional Review Board and Ethics Committee of the Northern Hospital. TPO was kindly provided by Genentech Inc (USA). Iscove's Modified Dulbecco's Medium (IMDM) and neurobasalTM medium were purchased from Invitrogen (USA). MACS CD34 multisort kit was purchased from Miltenyi Biotec (Germany). METHODS: CD34+ cells were isolated from human FL mononuclear cells using MACS CD34 multisort kit and cultured at 1 × 105/mL in IMDM, containing TPO for 60 days with weekly changes of half of the medium. After culturing for 30 and 60 days, the TPO-induced cells were resuspended in neurobasalTM medium containing 10% fetal brain extracts and plated in an 8-well BIOCOAT poly-D-Lysine Culture Slide and cul- tured for another 7 days. MAIN OUTCOME MEASURES: Cell number, viability, phenotype and expression of hemopoiesis-related and neurogenesis-related proteins were examined by trypan blue exclusion with hemocytometer, immunoblot, immunocytochemistry and flow cytometry. RESULTS: After 60 days of induction with TPO, the cell number increased by 4.6-fold compared to the ini- tial culture. Although the proportion of the cells expressing the hemopoietic stem cell associated antigen (CD34) decreased steadily, both proportions of the cultured FL-derived CD34+ cells expressing CD41a and CD61 remained unchanged, which still accounted for 10%. Noticeably, the proportions of the cells express- ing nestin and epidermal growth factor receptor increased significantly (both > 50%), whereas the expression of more mature neural or glial proteins [microtubule-associated protein-2 (MAP2), glial fibrillary acidic pro- tein (GFAP), oligodendrocyte marker O4 (O4)] markers on the cultured fetal liver derived-CD34+ cells were at lower levels. After another 7 days incubation in neurobasal? medium, these TPO-induced cells formed neurospheres, which were labeled with nestin, and differentiated into cells with morphological characteristics of neurons, astrocytes and oligodendrocytes, which were labeled with MAP-2, GFAP, and O4, respectively. CONCLUSION: TPO can induce FL-derived HSCs to differentiate or trans-differentiate into NSCs and its progenitors. | Ning Ma Dongchu Ma Yi Tao Yinghui Sun Di Lin Huiying Yu Jinlong Jian Wei Jia Boquan Jin | 2008 | Neural Regeneration Research2008，3，4： | 1 |
| 3 | Effect of dendritic cell/cytokine-induced killer cell immunobiological cancer therapy combined with adjuvant chemotherapy in patients with triple-negative breast cancer显示文摘Objective The aim of the present study was to investigate the effect of dendritic cell(DC)/cytokine-induced killer cell(CIK) immunobiological cancer therapy in patients with triple-negative breast cancer(TNBC) who underwent adjuvant chemotherapy. Methods From January 2010 to October 2013, 120 patients with postoperative TNBC were recruited and included in the study. Patients were enrolled in one of two groups according to whether they accepted DC/CIK immunobiological cancer therapy during adjuvant chemotherapy; the patients in the DC/CIK group underwent adjuvant chemotherapy combined with DC/CIK immunobiological cancer therapy, and the control group underwent adjuvant chemotherapy alone. When six cycles of adjuvant chemotherapy and six cycles of DC/CIK immunobiological cancer therapy had been completed, differences between the two groups with regard to quality of life(Qo L), immunological indicators(CD3, CD4, CD8, and NK cell levels), disease-free survival(DFS), and side effects of chemotherapy and DC/CIK treatment were evaluated.Results In the DC/CIK group, the proportion of NK cells and CD3+ and CD4+ T-cell subgroups significantly increased, and the proportion of CD8+ cells decreased when they were compared before and after DC/CIK therapy(P < 0.05). However, there were no significant changes in the control group. By the final follow-up, DFS of the treatment group and the control group was 38.4 and 34.2 months, respectively. The Qo L improved in the patients treated with chemotherapy plus DC/CIK therapy compared with the patients treated with chemotherapy alone, and the difference between groups was significant(P < 0.05). The side effects of two groups were tolerable and not significantly different between the two groups.Conclusion The DC/CIK treatment had potential benefits for patients with TNBC compared with the control group, and was not associated with any obvious side effects. Therefore, DC/CIK therapy is a safe and effective method for the treatment of TNBC. | Ranran Zhang Wanqing Xie Tao Han Yongye Liu Zhaozhe Liu Fang Guo Yaling Han Zhenyu Ding Yinghui Sun Dongchu Ma Xiaodong Xie | 2015 | The Chinese-German Journal of Clinical Oncology2015，14，1： | 1 |
| 4 | The influence of autologous cytokine-induced killer cell treatment on the objective efficacy and safety of gefitinib in advanced non-small cell lung cancer显示文摘Objective The aim of the study was to observe the influence of autologous cytokine-induced killer cell(CIK) treatment on the objective efficacy and safety of gefitinib in advanced non-small cell lung cancer(NSCLC).Methods Sixty-six patients with NSCLC received gefitinib as second-line treatment. They were randomly divided into 2 groups, and informed consent forms were signed before grouping. Gefitinib was administrated to the control group, and autologous CIK treatment was added to the observation group. The objective treatment and adverse reactions were evaluated in both groups. Results The objective response rate(ORR) and the disease control rate(DCR) of the observation group were slightly higher than those of the control group, although no statistical differences were found between the 2 groups(P > 0.05). The incidences of diarrhea, fatigue, anorexia, oral ulcers, and myelosuppression in the observation group were much lower than those in the control group(P < 0.05). However, there were no statistical differences between the incidences of skin rash, and liver and kidney toxicities(P > 0.05). Conclusion Autologous CIK in combination with gefitinib is effective as second-line treatment for advanced NSCLC, and can significantly reduce adverse reactions and improve the objective efficacy. | Shuxian Qu Zhaozhe Liu Zhendong Zheng Zhenyu Ding Tao Han Fang Guo Jianing Qiu Xiaodong Xie Dongchu Ma | 2015 | The Chinese-German Journal of Clinical Oncology2015，14，2： | 0 |
| 5 | OBSERVATION OF MEGAKARYOCYTOPOIESIS IN HUMAN FETUS BY IMMUNOCYTOCHEMICAL STAINING WITH ANTI-PLATELET GLYCOPROTEIN ⅡB /ⅢA MONOCLONAL ANTIBODY显示文摘Fetal liver tissues obtained from 28 human fetuses with gestation age from 3 to 6 months and fetal bone marrow from 35 human fetuses from 3 to 7 months were observed by immunochemical staining with anti-platelet GPⅡ b / Ⅲa monoclonal antibody and ABC technique. In the fetal liver, megakaryocytes were wholly located among growing fetal liver cells and near foci of hemopoiesis. Some megakaryocytes in the fetal liver were small7890- lymphoid-like megakaryocytes. The size of megakaryocytes both in the fetal liver (14.79 ± 4.52μm) and in the fetal bone marrow (16.08±7.39 μm) was small, which did not vary significantly over the gestation age ranging from 3 to 6 or 7 months. However, the maturation stage of megakaryocytes in the fetal liver shifted to more mature stage with the advancement of gestation, although the maturation stage of megakaryocytes in the fetal bone marrow did not change with the advancement of gestation from 4 to 7 months, the megakaryocyte in the fetal bone marrow was less mature | MA Dongchu CHU Junjie SUN Yinghui CHANG Kuizhong ZUO Wei (Department of Experimental Medicine, General Hospital of Shenyang Shenyang, China) Correspondence: Dr. MA Dongchu, Department of Experimental Medicine, General Hospital of Shenyang, 83, Wenhua Road, Shenyang, Liaoning 110015, China. | 1994 | 中国实验血液学杂志1994，2，2： | 0 |
| 6 | shRNA下调MTDH基因表达抑制乳腺癌细胞上皮-间质转化(英文)显示文摘Objective: Metadherin (MTDH) could regulate epithelial-mesenchymal transition (EMT), and is involved in tumor metastasis.This study was designed to observe the effect of MTDH-short hairpin RNA (shRNA) on EMT, and the role of MTDH in breast tumor metastasis. Methods: RNA interference plasmid that can express shRNA targeting MTDH or shRNA-negative plasmid that does not match any known human coding mRNA was designed, constructed and named MTDH-shRNA and MTDH-shRNA-neg, which were transiently transfected into MDA-MB-231 cells using Lipofectamine TM2000. After 48 h, the levels of MTDH, E-cadherin and α-SMA expression were determined by reverse transcription-polymerase chain reactin (RT-PCR), Western blot. The invasion and immigration potential was examined by Transwell chamber invasion or migration assay. Results: Compared with MDA-MB-231, the MTDH mRNA level was down-regulated by 41.2%, the MTDH protein level was down-regulated by 40.3%. The invasion and immigration potential of MDA-MB-231 cells was decreased after transfection of MTDH-shRNA. Compared with MDA-MB-231 or MTDH-shRNA-neg, the mRNA and protein level of α-SMA was reduced and E-candherin were increased in MTDH-shRNA, with statistical significance. Conclusion: Downregulation of MTDH increase E-candherin expression and reduced α-SMA expression, which inhibit EMT in MDA-MB-231 cells. This knockdown significantly suppresse migration and invasion in MDA-MB-231 cells. | Heng Cao Zhaozhe Liu Dongchu Ma Zhenyu Ding Cheng Du Xiaodong Xie | 2013 | The Chinese-German Journal of Clinical Oncology2013，12，7： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员